Search | Clinical Trials Finder

Conditions: Cystic Fibrosis Liver Disease
Interventions: Transient Elastography (TE); Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 26 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Chronic Pancreatitis
Interventions: Not listed
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Liprotamase, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 23 more

Conditions: Pancreatic Cancer
Interventions: Synthetic Human Secretin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 1 Month to 12 Months
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more

Conditions: Diarrhea, Exocrine Pancreatic Insufficiency, Abdominal Pain
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions: placebo, repaglinide; Drug
Lead sponsor: Arbelaez, Ana Maria; Individual
Eligibility: 12 Years to 24 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Exocrine Pancreatic Insufficiency
Interventions: RELiZORB, Placebo; Device
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Exocrine Pancreatic Insufficiency
Interventions: VIOKASE 16; Drug
Lead sponsor: Axcan Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Gainesville, Florida • Mayo Clinic- Rochester, Minnesota

Conditions: Cystic Fibrosis, Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more

Conditions: Shwachman-Diamond Syndrome, Shwachman-Diamond Syndrome-Like
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Timeline: 2016 – 2090
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio

Conditions: Exocrine Pancreatic Insufficiency, Chronic Pancreatitis
Interventions: Secretin (human synthetic) - ChiRhoClin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Interventions: Pancrelipase, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more

Conditions: Shwachman-Diamond Syndrome
Interventions: Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires; Diagnostic Test · Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Exocrine Pancreatic Insufficiency
Interventions: ANG003; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more

Conditions: Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase delayed release capsule, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 23
States / cities: Scottsdale, Arizona • Bristol, Connecticut • Tampa, Florida + 20 more

Conditions: Pancreatic Insufficiency
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neutropenia
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Exocrine Pancreatic Insufficiency (EPI), Pancreatitis
Interventions: RELiZORB; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Search by objective public record fields.

Longitudinal Assessment of Transient Elastography in Cystic Fibrosis

PAtient-CenTric Chronic Pancreatitis Registry (PACT-CP)

EASY: Extended Access to Sollpura Over Years

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Shwachman Diamond Syndrome Registry and Study

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

Phase 2 Study to Assess the Safety and Efficacy of ANG003

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Diabetes/ Endocrine Surveillance in SDS

Phase 1 Study to Assess Safety and Efficacy of ANG003

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

Pancreatic Insufficiency Secondary to Tobacco Exposure

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)